152 related articles for article (PubMed ID: 32002304)
21. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation.
Papadopoulos N; Nédélec A; Derenne A; Şulea TA; Pecquet C; Chachoua I; Vertenoeil G; Tilmant T; Petrescu AJ; Mazzucchelli G; Iorga BI; Vertommen D; Constantinescu SN
Nat Commun; 2023 Apr; 14(1):1881. PubMed ID: 37019903
[TBL] [Abstract][Full Text] [Related]
23. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
[TBL] [Abstract][Full Text] [Related]
24. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
25. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
Salati S; Genovese E; Carretta C; Zini R; Bartalucci N; Prudente Z; Pennucci V; Ruberti S; Rossi C; Rontauroli S; Enzo E; Calabresi L; Balliu M; Mannarelli C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
Sci Rep; 2019 Jul; 9(1):10558. PubMed ID: 31332222
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
28. Targeting the CALR interactome in myeloproliferative neoplasms.
Pronier E; Cifani P; Merlinsky TR; Berman KB; Somasundara AVH; Rampal RK; LaCava J; Wei KE; Pastore F; Maag JL; Park J; Koche R; Kentsis A; Levine RL
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429377
[TBL] [Abstract][Full Text] [Related]
29. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
30. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
Araki M; Yang Y; Imai M; Mizukami Y; Kihara Y; Sunami Y; Masubuchi N; Edahiro Y; Hironaka Y; Osaga S; Ohsaka A; Komatsu N
Leukemia; 2019 Jan; 33(1):122-131. PubMed ID: 29946189
[TBL] [Abstract][Full Text] [Related]
31. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
32. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C;
J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676
[TBL] [Abstract][Full Text] [Related]
33. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
34. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
35. Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells.
Zhao L; Zhang S; Chen H; Kroemer G; Kepp O; Liu P
Methods Cell Biol; 2022; 172():99-114. PubMed ID: 36064229
[TBL] [Abstract][Full Text] [Related]
36. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
37. Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.
Zinke M; Nageswaran V; Reinhardt R; Burmeister T
Mol Diagn Ther; 2015 Oct; 19(5):329-34. PubMed ID: 26294037
[TBL] [Abstract][Full Text] [Related]
38. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
[TBL] [Abstract][Full Text] [Related]
39. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
40. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
Wang J; Hao J; He N; Ji C; Ma D
Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]